Risperidone for psychosis of Alzheimer's disease and mixed dementia: Results of a double-blind, placebo-controlled trial

International Journal of Geriatric Psychiatry

Volumn 20, Issue 12, 2005, Pages 1153-1157

  Brodaty, Henry ^a,i   Ames, David ^b   Snowdon, John ^c   Woodward, Michael ^d   Kirwan, Jeff ^e   Clarnette, Roger ^f   Lee, Emma ^g   Greenspan, Andrew ^h  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d AUSTIN HEALTH   (Australia)

^e PRINCESS MARGARET HOSPITAL   (New Zealand)

^f FREMANTLE HOSPITAL   (Australia)

^g Janssen Cilag EMEA Belgium   (Belgium)

^h JANSSEN RESEARCH AND DEVELOPMENT   (United States)

ⁱ PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Alzheimer's disease; Elderly; Mixed dementia; Psychosis; Risperidone

Indexed keywords

PLACEBO; RISPERIDONE;

AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FALLING; FEMALE; HUMAN; INJURY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NURSING HOME; PATIENT SATISFACTION; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESSNESS; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; DEMENTIA, VASCULAR; DOUBLE-BLIND METHOD; FEMALE; HOMES FOR THE AGED; HUMANS; MALE; MIDDLE AGED; NURSING HOMES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; TREATMENT OUTCOME;

EID: 29944436359     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.1409     Document Type: Article

References (16)

1. Brodaty H, Ames D, Snowdon J, et al. 2003. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 64: 134-143.
2. Cohen-Mansfield J, Billig N. 1986. Agitated behaviors in the elderly. I. A conceptual review. J Am Geriatr Soc 34: 711-721.
3. Dahlke F, Lohaus A, Gutzmann H. 1992. Reliability and clinical concepts underlying global judgments in dementia: implications for clinical research. Psychopharmacol Bull 28: 425-432.
4. De Deyn PP, Rabheru K, Rasmussen A, et al. 1999. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53: 946-955.
5. Folstein MF, Folstein SE, McHugh PR. 1975. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
6. Grossman F, Okamoto A, Turkoz I, Gharabawi G. 2004. Risperidone in the treatment of elderly patients with psychosis of Alzheimer's disease and related dementias. J Am Geriatr Soc 52: 852-853.
7. Haupt M, Kurz A, Jänner M. 2000. A 2-year follow-up of behavioural and psychological symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord 11: 147-152.
8. Jeste DV, Finkel SI. 2000. Psychosis of Alzheimer's disease and related dementias: diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 8: 29-34.
9. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. 1999. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 60: 107-115.
10. Katz IR, Brodaty H, De Deyn PP, Mintzer J, Greenspan A. 2005. Risperidone in the treatment of psychosis of Alzheimer's Disease (PAD). A pooled analysis of 4 controlled trials. Poster presented at the Annual Scientific Meeting of the American Geriatrics Society (AGS), May 11-15 2005, Orlando, Florida, USA C109.
11. Laughren T. 2001. A regulatory perspective on psychiatric syndromes in Alzheimer disease. Am J Geriatr Psychiatry 9: 340-345.
12. Lopez OL, Wisniewski SR, Becker JT, Boller F, DeKosky ST. 1999. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol 56: 1266-1272.
13. Paulsen JS, Salmon DP, Thai LJ, et al. 2000. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 54: 1965-1971.
14. Reisberg B. 1988. Functional assessment staging (FAST). Psychopharmacol Bull 24: 653-659.
15. Reisberg B, Auer SR, Monteiro IM. 1996. Behavioral pathology in Alzheimer's disease (BEHAVE-AD) rating scale. Int Psychogeriatr 8(Suppl. 3): 301-308.
16. Schneider LS, Katz IR, Park S, Napolitano J, Martinez RA, Azen SP. 2003. Psychosis of Alzheimer disease: validity of the construct and response to risperidone. Am J Geriatr Psychiatry 11: 414-425.